Drugs / allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07274059 | Mar 2025 → Dec 2035 expected | systemic lupus erythematosus | Chengdu Ucello Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07274059 ↗ |
| Modality | Cell therapy | “allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T)” NCT07274059 ↗ |
| Route | Intravenous | “intravenous injection of allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA” NCT07274059 ↗ |
| Target | CD19 | “CAR-T targeting CD19 and BCMA” NCT07274059 ↗ |